PRECISION MEDICINE AND TARGETED IMMUNOTHERAPY IN AXIAL SPONDYLOARTHRITIS: CONTEMPORARY STRATEGIES, MECHANISTIC INSIGHTS, AND FUTURE DIRECTIONS

Vahobov Hikmatilla Tulkinjon ugli
Nurullayev Avazbek Rustamboy ugli
https://doi.org/10.5281/zenodo.18796859

ARTICLE INFO

Received: 25th February2026
Accepted: 27th February 2026
Online: 26th February 2026

KEYWORDS

Genetic predisposition plays a central role in disease pathogenesis. The association with the HLA-B27 allele remains one of the strongest known links between a human leukocyte antigen and a specific rheumatic disease

ABSTRACT

Axial spondyloarthritis represents a chronic, immune-mediated inflammatory disorder characterized predominantly by inflammation of the sacroiliac joints and spine, progressive structural remodeling, and varying degrees of functional impairment. Ankylosing spondylitis constitutes the radiographic form of axial spondyloarthritis and remains the most extensively studied phenotype within this disease spectrum. Traditionally conceptualized as a musculoskeletal disorder leading to spinal ankylosis and disability, axial spondyloarthritis is now recognized as a complex systemic condition involving genetic susceptibility, dysregulated innate and adaptive immune responses, and environmental triggers. The modern therapeutic landscape has shifted dramatically over the past two decades, transitioning from symptom-centered management to targeted immunomodulation and personalized treatment strategies.

Introduction

Axial spondyloarthritis represents a chronic, immune-mediated inflammatory disorder characterized predominantly by inflammation of the sacroiliac joints and spine, progressive structural remodeling, and varying degrees of functional impairment. Ankylosing spondylitis constitutes the radiographic form of axial spondyloarthritis and remains the most extensively studied phenotype within this disease spectrum. Traditionally conceptualized as a musculoskeletal disorder leading to spinal ankylosis and disability, axial spondyloarthritis is now recognized as a complex systemic condition involving genetic susceptibility, dysregulated innate and adaptive immune responses, and environmental triggers. The modern therapeutic landscape has shifted dramatically over the past two decades, transitioning from symptom-centered management to targeted immunomodulation and personalized treatment strategies.

The epidemiology of axial spondyloarthritis reveals a higher prevalence in young adults, particularly men, with disease onset typically occurring before the age of forty. The socioeconomic burden is substantial, as the condition frequently affects individuals during their most productive years. Chronic back pain, stiffness, fatigue, and progressive limitation of spinal mobility impair occupational capacity and diminish overall quality of life. Moreover, extra-articular manifestations such as uveitis, inflammatory bowel disease, and psoriasis

contribute to disease complexity and necessitate multidisciplinary care. Early recognition and effective therapeutic intervention are therefore essential to prevent irreversible structural damage and long-term disability.

Genetic predisposition plays a central role in disease pathogenesis. The association with the HLA-B27 allele remains one of the strongest known links between a human leukocyte antigen and a specific rheumatic disease. However, HLA-B27 alone does not fully explain disease development, as many carriers remain asymptomatic. Advances in molecular immunology have identified additional genetic loci related to cytokine signaling, antigen processing, and immune regulation. Among these, pathways involving tumor necrosis factor alpha and interleukin-17 have emerged as critical mediators of inflammation and structural progression in axial spondyloarthritis.

Historically, therapeutic management relied heavily on non-steroidal anti-inflammatory drugs as first-line agents. These medications effectively reduce pain and stiffness and remain foundational in early disease control. Nevertheless, prolonged use is associated with gastrointestinal, renal, and cardiovascular risks. The recognition that persistent inflammation drives structural damage prompted investigation into disease-modifying approaches capable of altering long-term outcomes rather than merely alleviating symptoms.

The advent of biologic therapies targeting tumor necrosis factor alpha marked a paradigm shift in the treatment of axial spondyloarthritis. These agents demonstrated significant improvements in disease activity, functional indices, and imaging outcomes. Subsequent research elucidated the pivotal role of the interleukin-17 axis in enthesitis and new bone formation, leading to the development of monoclonal antibodies directed against interleukin-17A and related cytokines. More recently, small-molecule inhibitors targeting intracellular signaling pathways such as Janus kinase have expanded therapeutic options further.

Despite these advances, several challenges persist. Not all patients respond adequately to initial biologic therapy, and secondary loss of response remains a clinical concern. Safety considerations, including infection risk and long-term immunosuppression effects, require careful monitoring. Economic factors and access to biologic agents vary globally, influencing real-world treatment implementation. Furthermore, heterogeneity in disease phenotype and immune activation patterns suggests that a uniform treatment algorithm may not be optimal for all individuals.

Current international recommendations emphasize treat-to-target strategies, aiming for sustained remission or low disease activity. This approach necessitates regular monitoring using validated tools such as the Ankylosing Spondylitis Disease Activity Score and imaging modalities including magnetic resonance imaging. The integration of clinical assessment, laboratory biomarkers, and patient-reported outcomes forms the basis of individualized therapeutic decisions.

Emerging concepts in precision medicine seek to stratify patients according to molecular signatures, genetic markers, and cytokine profiles to optimize therapeutic selection. Such strategies aim to minimize trial-and-error prescribing and improve cost-effectiveness while maximizing clinical benefit. Additionally, ongoing research explores combination regimens,

sequential biologic switching, and early intervention in non-radiographic disease stages to prevent irreversible structural changes.

The global COVID-19 pandemic introduced additional complexity into immunosuppressive therapy management. Concerns regarding infection susceptibility, vaccination responses, and continuity of biologic treatment required rapid adaptation of clinical guidelines. These experiences underscored the importance of flexible, evidence-based recommendations responsive to emerging data.

The present review examines the evolution of therapeutic paradigms in axial spondyloarthritis, emphasizing the transition toward targeted immunotherapy and personalized management. By synthesizing current clinical evidence, guideline recommendations, and mechanistic insights, this analysis aims to provide a comprehensive overview of contemporary treatment strategies and future research directions.

Materials and Methods

This comprehensive narrative review was conducted through systematic examination of peer-reviewed literature published in international rheumatology journals. Clinical trials, meta-analyses, and guideline documents were identified through database searches focusing on pharmacologic interventions in axial spondyloarthritis. Emphasis was placed on randomized controlled trials evaluating non-steroidal anti-inflammatory drugs, conventional disease-modifying antirheumatic drugs, tumor necrosis factor inhibitors, interleukin-17 inhibitors, dual cytokine blockade agents, and Janus kinase inhibitors.

Guidelines from leading rheumatology organizations were analyzed to assess the evolution of therapeutic recommendations. Safety data, efficacy endpoints, radiographic progression outcomes, and patient-reported measures were synthesized to evaluate comparative effectiveness. Mechanistic studies elucidating cytokine signaling and immune pathways were incorporated to contextualize therapeutic targets within disease pathophysiology.

Results

The cumulative evidence demonstrates a clear evolution from symptomatic management to targeted immunotherapy. Non-steroidal anti-inflammatory drugs remain the recommended initial therapy, particularly for patients with active inflammatory back pain. Continuous rather than on-demand dosing may provide superior control of inflammation, although long-term safety considerations necessitate individualized risk assessment.

Tumor necrosis factor inhibitors significantly reduce disease activity and improve functional outcomes in patients with inadequate response to non-steroidal anti-inflammatory drugs. Radiographic studies indicate potential slowing of structural progression with sustained suppression of inflammation. These agents have established safety profiles, though vigilance for opportunistic infections remains essential.

Interleukin-17 inhibitors represent a major advancement, particularly for patients who exhibit inadequate response or intolerance to tumor necrosis factor inhibitors. Clinical trials demonstrate rapid improvement in pain, stiffness, and mobility, with durable efficacy over extended follow-up. Dual inhibition of interleukin-17A and interleukin-17F has shown enhanced response rates in recent studies, suggesting broader cytokine blockade may provide incremental benefit.

Janus kinase inhibitors offer an oral therapeutic alternative targeting intracellular signaling cascades. Trials indicate meaningful reductions in disease activity among patients refractory to biologic therapy. While overall safety data are encouraging, long-term cardiovascular and thromboembolic risks require continued surveillance.

Conventional disease-modifying agents such as sulfasalazine exhibit modest efficacy primarily in peripheral arthritis rather than axial disease. Their role in modern treatment algorithms has diminished but remains relevant in selected clinical contexts.

Collectively, these findings illustrate a diversified therapeutic armamentarium enabling tailored intervention based on disease phenotype, comorbidity profile, and prior treatment response.

Discussion

The transformation of axial spondyloarthritis management reflects advances in immunology and translational research. Identification of key cytokine pathways enabled development of biologic and targeted synthetic agents capable of interrupting inflammatory cascades at specific molecular checkpoints. The treat-to-target strategy has redefined therapeutic goals, prioritizing remission and prevention of structural damage.

Nevertheless, several unresolved issues warrant attention. Biomarkers predictive of therapeutic response remain insufficiently validated. Some patients exhibit primary non-response to tumor necrosis factor inhibitors yet respond favorably to interleukin-17 blockade, suggesting heterogeneity in dominant inflammatory pathways. Precision medicine approaches incorporating genomic and proteomic profiling may facilitate more rational drug selection.

Safety considerations remain integral to long-term management. Balancing effective immunosuppression with infection risk requires careful patient selection and monitoring. Vaccination strategies and management during infectious outbreaks illustrate the dynamic interplay between rheumatologic care and public health considerations.

Economic sustainability also influences therapeutic accessibility. Biologic and targeted synthetic agents impose substantial financial burden on healthcare systems. Biosimilars and cost-effectiveness analyses play increasingly important roles in policy decisions.

Future research directions include early intervention trials in non-radiographic disease, exploration of combination biologic therapy, and investigation into mechanisms of new bone formation independent of inflammation. Understanding structural progression pathways may enable development of therapies specifically targeting ankylosis.

Conclusion

The management of axial spondyloarthritis has evolved from reliance on symptomatic relief to implementation of targeted immunotherapy guided by treat-to-target principles. Tumor necrosis factor inhibitors, interleukin-17 inhibitors, and Janus kinase inhibitors have expanded therapeutic possibilities, enabling individualized strategies for diverse patient populations.

Despite remarkable progress, ongoing research is essential to refine patient stratification, optimize long-term safety, and address unmet clinical needs. As molecular understanding deepens and precision medicine advances, future therapeutic paradigms are

expected to become increasingly personalized, improving functional outcomes and quality of life for individuals living with axial spondyloarthritis..

References:

1.Abdurakhmanova, N. M., Ahmedov, K. S., & Turaev, I. A. (2022). Modern methods of treatment of patients with ankylosing spondylitis. International Journal of Advance Scientific Research, 2(11), 112-118.

2.Turaev, S. Z. I., & Rakhimov, S. (2023). ASSESSMENT OF THE QUALITY OF LIFE IN PATIENTS WITH CHRONIC KIDNEY DISEASE IN THE PRACTICE OF HEMODIALYSIS. Journal of Modern Educational Achievements, 6(6), 103- 109.

3.Rakhimova, M. B., Akhmedov, K. S., Rakhimov, S. S., & Zaripov, S. I. (2023). Extrasceletal Manifestations in Patients with Ankylosing Spondylitis. Journal of Coastal Life Medicine, 11, 1315-1321.

4.Zaripov, S. I., & Abdurakhmanova, N. M. (2023). Quality of life of End-Stage Renal Disease (ESRD) patients receiving hemodialysis: influencing factors and approaches to correction. Texas Journal of Multidisciplinary Studies, 21, 14-17.

5.Abdurakhmanova, N. M., Zaripov, S. S., & Turaev, I. A. (2023). THE EFFECT OF CLIMATEGEOGRAPHICAL FACTORS ON RHEUMATOID ARTHRITIS ACTIVITY. World Bulletin of Public Health, 18, 67-69.

6.S. I. Zaripov and N. M. B. Abdurakhmanova, "The Relationship Between Systemic Sclerosis and Anti-Fibrillarin Antibodies," Journal of Modern Educational Achievements, vol. 6, no. 6, pp. 235-238, 2024.

7.S. I. Zaripov, I. A. Turaev, and S. S. Rakhimov, "Quality of Life in Patients with Chronic Kidney Disease Receiving Program Hemodialysis and Possible Ways of Its Correction," Uzbek Medical Journal, vol. 3, no. 5, 2022.

8.Umarova, Z. F., Jumanazarov, S. B., Zaripov, S. I., & Khaydarov, R. M. (2024). Quality of life in patients with chronic kidney disease in the V stage receiving program hemodialysis and possible ways of its correction. Journal of Medicine and Innovations.

9.Istamovich, Z. S., Sadullayevich, A. K., & Mirza-Bakhtiyarkhanovna, A. N. (2023). The significance of autoantibodies in the pathogenesis of systemic sclerosis (literature review). Journal of Biomedicine and Practice, 8(2).

10.Абдурахманова, Н. М., Ахмедов, Х. С., & Зарипов, С. И. (2024). ИММУНОПАТОГЕНЕТИЧЕСКОЕ ЗНАЧЕНИЕ АУТОАНТИТЕЛ ПРОТИВ ФИБРИЛЛИНА ПРИ СИСТЕМНОЙ СКЛЕРОДЕРМИИ.

11.Axmedov, I. A., Xalmetova, F. I., & Zaripov, S. I. (2024). Rematoid artrit kasalligi bo ‘lgan bemorlarda yurak qon-tomir tizimidagi buzulishlarni erta aniqlashda yurak ritmi buzilishlarining o ‘rni.

12.Rakhmatov, A. M., & Zaripov, S. I. (2024). Gout and its association with gouty nephropathy: an analysis of 46 patients. Современные подходы и новые исследования в современной науке, 3(16), 100-102.

13.Рахимова, М. Б., Ахмедов, Х. С., & Халметова, Ф. И. (2025). ОЦЕНКА ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ.

14.Rakhimova, M., Akhmedov, K., Buranova, S., & Tursunova, L. (2022). Evaluation of cardiovascular events in patients with ankylosing spondylitis after COVID-19.

15.Шовкатова, М. Н., & Рахимова, М. Б. (2025). ИСКУССТВЕННЫЙ ИНТЕЛЛЕКТ В ЦИФРОВОЙ СТРАТИФИКАЦИИ И ДИНАМИЧЕСКОМ КОНТРОЛЕ СЕРДЕЧНО-СОСУДИСТОГО РИСКА У БОЛЬНЫХ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ И РЕВМАТОИДНЫМ АРТРИТОМ. FARS International Journal of Education, Social Science & Humanities., 13(12), 7-14.
16.Rakhimova, M. B., Akhmedov, K. S., & Turaev, Y. A. (2021). Endothelial dysfunction as a link in the pathogenesis of ankylosing spondylitis against the background of a new coronavirus infection. ACADEMICIA: An International Multidisciplinary Research Journal, 11(3), 2493-2498.
17.Rakhimova, M. B., Akhmedov, K. S., Rakhimov, S. S., & Zaripov, S. I. (2023). Extrasceletal Manifestations in Patients with Ankylosing Spondylitis. Journal of Coastal Life Medicine, 11, 1315-1321.
18.Abdurakhmanova, N., Akhmedov, K., Jabbarov, O., Rakhimova, M., Tagaeva, M., Khalmetova, F., & Tursunova, L. (2022). Clinical And Diagnostic Significance Of Anti-Cd74 In Patients With Ankylosing Spondylitis Of Uzbek Population. Journal of Positive School Psychology http://journalppw. com, 6(6), 9358-9364.
19.Rakhimova, M. B., & Akhmedov, K. S. (2021). The impact of sequelae of covid-19 on the course of ankylosing spondylitis. Central Asian journal of medicine, 2021(4), 58-63.
20.Rakhimova, M. B. (2023). Impared endothelial dysfunction in covid-19: an overview of evidence, biomarkers in patients with ankylosing spondylitis. IMRAS, 6(7), 20-27.
21.Буранова, С. Н., & Бахронова, Ю. Б. (2025). ПРОСПЕКТИВНЫЙ АНАЛИЗ ОСОБЕННОСТЕЙ КЛИНИЧЕСКИХ ПРОЯВЛЕНИЙ СИСТЕМНОЙ СКЛЕРОДЕРМИИ В ЗАВИСИМОСТИ ОТ КЛИНИЧЕСКОЙ ФОРМЫ ЗАБОЛЕВАНИЯ. AMERICAN JOURNAL OF EDUCATION AND LEARNING, 3(9), 581-583.
22.Ахмедов, Х. С., Абдурахманова, Н. М., Буранова, С. Н., Халметова, Ф. И., Рахимова, М. Б., Нуриллаев, Б. А., & Очилов, И. А. (2025). УЧЕБНО-МЕТОДИЧЕСКИЙ КОМПЛЕКС ПО ПРЕДМЕТУ.
23.Khalmetova, F. I., Akhmedov, K. S., Buranova, S. N., Rakhimova, M. B., Rakhimov, S. S., & Abdurakhimova, L. A. (2023). Immunological Features of Reactive Arthritis of Various Etiologies. Journal of Coastal Life Medicine, 11, 1322-1325.
24.Akhmedov, K., Abdurakhmanova, N., & Buranova, S. (2023). Features of the clinical course of rheumatoid spice against the background of the influence of xenobiotics. American Journal of Interdisciplinary Research and Development, 12, 142-147.
25.Buranova, S. (2021). Method of treatment aimed at the dynamics of cartilage oligomer matrix protein (COMP) in patients with osteoarthritis.
26.Buranova, S. N. (2021). Akhmedov Kh. S., Razakova FS The Importance of Treatment Aimed at the Dynamics of Cartilage Oligomer Matrix Protein (COMP) in Patients with the Knee Joint Osteoarthritis. American Journal of Medicine and Medical Sciences, 11(2), 148-153.
27.Buranova, S., & Akhmedov, K. (2021). Cartilage oligomeric matrix protein (comp) in early diagnosis of osteoarthritis.
28.Khalmetova, F., Axmedov, X., Buranova, S., & Botirbekov, A. (2023). GENETIC ASPECTS OF REACTIVE ARTHRITIS. Scientific journal of the Fergana State University, (1), 133-133.
29.Xalmetova, F. I., Akhmedov, X. S., & Buranova, S. N. (2022). The role of imaging techniques in the assessment of structural changes in the joint in reactive arthritis. Academicia Globe, 3(03), 186-189.

30.Buranova, S. N., & Khalmetova, F. I. (2025). STUDY OF THE ROLE OF TGF-B, LOX, AND CXCL10 IN THE PROGRESSION OF SKIN AND VISCERAL LESIONS IN PATIENTS WITH SYSTEMIC SCLERODERMA. JOURNAL OF MULTIDISCIPLINARY BULLETIN, 8(9), 43-46.
31.Khalmetova, F. I., Akhmedov, K. S., Turayev, I. A., & Zaripov, S. I. Реактив артритни даволашда замонавий патогенетик ёндашувлар. 2024. TTA AXBOROTNOMASI. Bb, 63-65.
32.Ахмедов, Х. С., Абдурахманова, Н. М., & Халметова, Ф. И. (2017). Влияние различных физических факторов климата на течение ревматоидного артрита. Universum: медицина и фармакология, (3 (37)), 12-15.
33.Абдурахимов, А. Г., & Халметова, Ф. И. (2023). Нестероидные противовоспалительные препараты у пациентов с деформирующим остеоартрозом и артериальной гипертензией: анализ влияния целекоксиба и мелоксикама на антигипертензивные средства. Оптимизация лечения. Атеросклероз, 19(3), 186-187.
34.Khalmetova, F. I., Akhmedov, K. S., & Razakova, F. S. (2021). Comparative analysis of the clinical presentation of reactive arthritis.
35.Khalmetova, F. I., Akhmedov, X. S., & Alibekova, G. A. (2023). Features of the course of the joint syndrome in various forms of reactive arthritis. Galaxy International Interdisciplinary Research Journal, 11(4), 832-837.
36.Шарипова, Н. В., Худайберганов, А. С., Рахимов, Б. Б., & Наврузов, Э. Б. Гигиенические требования к безопасности пищевой продукции. СанПиН РУз,(0283-10).
37.Салихова, Н. С., Косимов, Р. А., Юлдашева, З. Р., Шайхова, Г. И., Эрматов, Н. Ж., & Рахимов, Б. Б. (2016). Санитарно-эпидемиологические требования к организации питания обучающихся в общеобразовательных школах, учреждениях средне специального профессионального образования. СанПиН.–2016, 0288-10.
38.Nurmatov, B., & Rakhimov, B. (2022). Study of virus contamination of indoor air and surfaces of hospital which specialized in the treatment of COVID-19 patients.
39.Рахимов, Б. Б., Уринов, А. М., Шайхова, Л. И., & Камилова, А. Ш. (2017). Выявление факторов риска при ожирении у детей дошкольного возраста, проживающих в г. Ташкенте.
40.Shaykhova, G. I., & Rakhimov, B. B. (2014). Promotion of the principles of rational nutrition in obesity. Medical Journal of Uzbekistan,(2), 138.